---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-069902"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-06-18T13:02:06+00:00"
generated_at: "2026-06-18T13:03:20.941936+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki

## Summary
- Plans to submit RPDD request to FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms.
- If RPDD granted and tecarfarin approved, eligible for Priority Review Voucher valued ~$200M (recent sales $180M-$205M).
- Dual-track strategy: Global Pharma (CAD-1005, Phase 3-ready for HIT) and Rare Disease (tecarfarin for Kawasaki).
- Company to present at BIO International Convention June 22-25, 2026, seeking partnerships.
- Kawasaki disease is leading cause of acquired heart disease in children; up to 25% untreated develop CAAs.

## SEC filing metadata
- accession: 0001213900-26-069902
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-06-18T13:02:06+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026069902/0001213900-26-069902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026069902/ea0295234-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-069902
- JSON: https://secwatch.observer/filing/0001213900-26-069902.json
- Plain text: https://secwatch.observer/filing/0001213900-26-069902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.